Skip to main
ALC

ALC Stock Forecast & Price Target

ALC Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 36%
Hold 36%
Sell 9%
Strong Sell 0%

Bulls say

Alcon is set to benefit from an earlier than expected allergy season, which could bring a boost in sales for its allergy medication Pataday, a key driver in its Ocular Health segment. The company has a strong presence in the visioncare market with its popular brands like Dailies and Total1, and has a dominant position in the US contact lens market. Alcon has a consistent track record of delivering top-line growth and innovative products, and its end-markets are expected to improve in the early part of FY26 due to new product launches. With a solid growth profile and steady operating margin expansion, Alcon is positioned for growth and its valuation remains favorable compared to its historical average. Some key risks to this outlook include a weaker economy, delays in product rollouts, and increased competition in its various business segments.

Bears say

Alcon is facing competition in both its visioncare and surgical segments and has not seen the strong growth previously anticipated from new products in the market. Despite having one of the largest installed bases of eye surgical equipment and a portfolio of IOLs, operating margins have not expanded significantly and costs continue to grow, leaving shares range-bound and likely unable to support their premium valuation. Additionally, although Alcon operates in a large market with the potential for growth through new treatment options, there is high competition and the potential for weaker-than-expected uptake of these new products, resulting in lower-than-expected growth.

ALC has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 36% recommend Buy, 36% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alcon Inc. - Registered Shares and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alcon Inc. - Registered Shares (ALC) Forecast

Analysts have given ALC a Buy based on their latest research and market trends.

According to 11 analysts, ALC has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $89.32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $89.32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alcon Inc. - Registered Shares (ALC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.